Open AccessVedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Author(s) -
William J. Sandborn,
Brian G. Feagan,
Paul Rutgeerts,
Stephen B. Hanauer,
JeanFrédéric Colombel,
Bruce E. Sands,
Milan Lukáš,
Richard N. Fedorak,
Scott Lee,
Brian Bressler,
Irving H. Fox,
Maria Rosario,
Serap Sankoh,
Jing Xu,
Kristin Stephens,
Catherine Milch,
Asit Parikh
Publication year - 2013
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1215739
Subject(s) - vedolizumab , medicine , placebo , crohn's disease , maintenance therapy , cohort , clinical trial , gastroenterology , surgery , disease , chemotherapy , pathology , alternative medicine
The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom